Biorasis, which is developing the Glucowizzard minimally invasive biosensor for monitoring glucose in patients with diabetes, has secured $3 million from The Leona M. and Harry B. Helmsley Charitable Trust. The money "fills a critical need in financing that will enable Biorasis to move our technology forward to be ready for clinical trials," said Chief Operating Officer Ilze Krisst.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.